- Hospital volume-outcome relationship in vulvar cancer treatment: a Japanese Gynecologic Oncology Group study
-
- KMID: 2526369
- J Gynecol Oncol.
- 2021 Mar;32(2):e24.
- doi: 10.3802/jgo.2021.32.e24
-
- CITED
-
- Close
- SHARE
-
- Close
- Comments on: Peripheral blood BRCA1 methylation profiling to predict familial ovarian cancer
-
Kwon JS
- KMID: 2526379
- J Gynecol Oncol.
- 2021 Mar;32(2):e33.
- doi: 10.3802/jgo.2021.32.e33
-
- CITED
-
- Close
- SHARE
-
- Close
- Evaluating robotic surgical courses: structured training matters
-
Falconer H
- KMID: 2526384
- J Gynecol Oncol.
- 2021 Mar;32(2):e39.
- doi: 10.3802/jgo.2021.32.e39
-
- CITED
-
- Close
- SHARE
-
- Close
- Reviewer recognition in 2020
-
- KMID: 2526385
- J Gynecol Oncol.
- 2021 Mar;32(2):e41.
- doi: 10.3802/jgo.2021.32.e41
-
- CITED
-
- Close
- SHARE
-
- Close
- How to start niraparib in real-world Asian ovarian cancer patients?
-
Hong SH
- KMID: 2526382
- J Gynecol Oncol.
- 2021 Mar;32(2):e36.
- doi: 10.3802/jgo.2021.32.e36
-
- CITED
-
- Close
- SHARE
-
- Close
- Comments on: Safety and efficacy of 3D-printed templates assisted CTguided radioactive iodine-125 seed implantation for the treatment of recurrent cervical carcinoma after external beam radiotherapy
-
Shin HS
- KMID: 2526388
- J Gynecol Oncol.
- 2021 Mar;32(2):e50.
- doi: 10.3802/jgo.2021.32.e50
-
- CITED
-
- Close
- SHARE
-
- Close
- Lumping and splitting: The need for precision medicine and “personomics” in endometrial cancer
-
Reyes-Baez FE, Garzon S, Mariani A
- KMID: 2526383
- J Gynecol Oncol.
- 2021 Mar;32(2):e38.
- doi: 10.3802/jgo.2021.32.e38
-
- CITED
-
- Close
- SHARE
-
- Close
- Current status and future directions of ovarian cancer prognostic models
-
Kobayashi Y, Banno K, Aoki D
- KMID: 2526380
- J Gynecol Oncol.
- 2021 Mar;32(2):e34.
- doi: 10.3802/jgo.2021.32.e34
-
- CITED
-
- Close
- SHARE
-
- Close
- Implementation and evaluation of a novel subspecialty society fellows robotic surgical course: the SGO minimally invasive academy surgical curriculum
-
Boitano TK, Smith HJ, Cohen JG, Rossi EC, Kim KH
- KMID: 2526373
- J Gynecol Oncol.
- 2021 Mar;32(2):e26.
- doi: 10.3802/jgo.2021.32.e26
Objective: To evaluate the utility of a society-based robotic surgery training program for fellows in gynecologic oncology. Methods: All participants underwent a 2-day robotic surgery training course between 2015–2017. The course... -
- CITED
-
- Close
- SHARE
-
- Close
- Increased risk of herpes zoster in gynecological cancer patients receiving radiotherapy combined with chemotherapy: a need for paying attention to vaccines
-
Shin DH, Song KH
- KMID: 2526381
- J Gynecol Oncol.
- 2021 Mar;32(2):e35.
- doi: 10.3802/jgo.2021.32.e35
-
- CITED
-
- Close
- SHARE
-
- Close
- Post-LACC era: critical assessment not “all-or-none” is needed
-
Leitao Jr MM, Kim SI, Kim JW
- KMID: 2526386
- J Gynecol Oncol.
- 2021 Mar;32(2):e47.
- doi: 10.3802/jgo.2021.32.e47
-
- CITED
-
- Close
- SHARE
-
- Close
- Recurrence risk factors in stage IA grade 1 endometrial cancer
-
Nwachukwu C, Baskovic M, Eyben RV, Fujimoto D, Giaretta S, English D, Kidd E
- KMID: 2526365
- J Gynecol Oncol.
- 2021 Mar;32(2):e22.
- doi: 10.3802/jgo.2021.32.e22
Objectives: Patients with early-stage endometrial cancers (EC) with disease recurrences have worse survival outcomes. The purpose of this study was to identify clinical and pathologic factors that predict for all... -
- CITED
-
- Close
- SHARE
-
- Close
- A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01)
-
Lee YJ, Lim MC, Kim BG, Ngoi NY, Choi CH, Park SY, Tan DS, Go Y, Lee JY
- KMID: 2526377
- J Gynecol Oncol.
- 2021 Mar;32(2):e31.
- doi: 10.3802/jgo.2021.32.e31
Background: The optimal treatment of BRCA wild-type patients with platinum-sensitive recurrent ovarian cancer remains unknown. Recently, there is an increase in the evidence to support the role of the combination... -
- CITED
-
- Close
- SHARE
-
- Close
- The 2020 Japan Society of Gynecologic Oncology guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer
-
Tokunaga H, Mikami M, Nagase S, Kobayashi Y, Tabata T, Kaneuchi M, Satoh T, Hirashima Y, Matsumura N, Yokoyama Y, Kawana K, Kyo S, Aoki D, Katabuchi H
- KMID: 2526387
- J Gynecol Oncol.
- 2021 Mar;32(2):e49.
- doi: 10.3802/jgo.2021.32.e49
The fifth edition of the Japan Society of Gynecologic Oncology guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer was published in 2020. The guidelines... -
- CITED
-
- Close
- SHARE
-
- Close
- Phase 2 single-arm study on the safety of maintenance niraparib in Japanese patients with platinum-sensitive relapsed ovarian cancer
-
Takehara K, Matsumoto T, Hamanishi J, Hasegawa K, Matsuura M, Miura K, Nagao S, Nakai H, Tanaka N, Tokunaga H, Ushijima K, Watari H, Yokoyama Y, Kase Y, Sumino S, Suri A, Itamochi H, Takeshima N
- KMID: 2526362
- J Gynecol Oncol.
- 2021 Mar;32(2):e21.
- doi: 10.3802/jgo.2021.32.e21
Objective: The primary objective of this study was to evaluate the safety of niraparib 300 mg/day in Japanese patients with platinum-sensitive, relapsed ovarian cancer in a maintenance setting. Methods: Phase 2,... -
- CITED
-
- Close
- SHARE
-
- Close
- Phase 2 single-arm study on the efficacy and safety of niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer
-
Okamoto A, Kondo E, Nakamura T, Yanagida S, Hamanishi J, Harano K, Hasegawa K, Hirasawa T, Hori K, Komiyama S, Matsuura M, Nakai H, Nakamura H, Sakata J, Tabata T, Takehara K, Takekuma M, Yokoyama Y, Kase Y, Sumino S, Soeda J, Suri A, Aoki D, Sugiyama T
- KMID: 2526354
- J Gynecol Oncol.
- 2021 Mar;32(2):e16.
- doi: 10.3802/jgo.2021.32.e16
Objective: To evaluate the efficacy and safety of niraparib in Japanese women with heavily pretreated ovarian cancer. Methods: This Phase 2 open-label, single-arm study enrolled Japanese women with homologous recombination deficiency-positive... -
- CITED
-
- Close
- SHARE
-
- Close
- Radiotherapy combined with chemotherapy increases the risk of herpes zoster in patients with gynecological cancers: a nationwide cohort study
-
Lee PY, Lai JN, Chen SW, Lin YC, Chiu LT, Wei YT
- KMID: 2526350
- J Gynecol Oncol.
- 2021 Mar;32(2):e13.
- doi: 10.3802/jgo.2021.32.e13
Objective: This study aimed to determine the effect of radiotherapy (RT) on the risk of herpes zoster (HZ) in patients with gynecological cancers via a nationwide population-based study. Methods: Based on... -
- CITED
-
- Close
- SHARE
-
- Close
- Safety and efficacy of 3D-printed templates assisted CT-guided radioactive iodine-125 seed implantation for the treatment of recurrent cervical carcinoma after external beam radiotherapy
-
Liu Y, Jiang P, Zhang H, Wang J
- KMID: 2526352
- J Gynecol Oncol.
- 2021 Mar;32(2):e15.
- doi: 10.3802/jgo.2021.32.e15
Objective: To investigate the safety and efficacy of 3-dimensional (3D) printing noncoplanar templates (PNCT) assisted computer tomography (CT) guided radioactive125I seed implantation (RISI) for the treatment of recurrent cervical carcinoma... -
- CITED
-
- Close
- SHARE
-
- Close
- Cost-effectiveness of olaparib versus routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore
-
Tan DS, Chan JJ, Hettle R, Ghosh W, Viswambaram A, Yu CC
- KMID: 2526375
- J Gynecol Oncol.
- 2021 Mar;32(2):e27.
- doi: 10.3802/jgo.2021.32.e27
Objective: To evaluate the cost-effectiveness of olaparib as a maintenance treatment versus routine surveillance (RS) in patients with BRCA mutated (BRCAm) advanced ovarian cancer (OC) following response to first-line platinum-based... -
- CITED
-
- Close
- SHARE
-
- Close
- Peripheral blood BRCA1 methylation profiling to predict familial ovarian cancer
-
Jung Y, Hur S, Liu J, Lee S, Kang BS, Kim M, Choi YJ
- KMID: 2526367
- J Gynecol Oncol.
- 2021 Mar;32(2):e23.
- doi: 10.3802/jgo.2021.32.e23
Objective: Familial cancer appears at a young age and its incidence is increasing. About 12% of familial ovarian cancer cases are associated with BRCA1/2 mutations (BRCAm). In this study, we... -
- CITED
-
- Close
- SHARE
-
- Close
